KOSDAQBiotech & Pharma389650

Nextbiomedical

₩23,700▲ 1.07%2026-11-18 close
Market Cap
₩196.3B
Turnover
₩200M
Volume
8.9K
Shares out.
8.3M
PER
—
PBR
4.7×
EPS
-₩521
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Sales Grow, Losses Persist for Four Quarters

Revenue has risen for three straight quarters through the third quarter of 2026, and operating losses have narrowed since the second quarter of 2026, while the net loss attributable to controlling shareholders widened sharply to KRW 3.47 billion in the third quarter.

  1. 1

    Revenue for 2025 was KRW 16.5 billion, up 72.7% from the prior year, and the operating loss narrowed to KRW 720 million.

  2. 2

    Third-quarter 2026 revenue was KRW 5.25 billion, up 6.4% year on year, but the net loss attributable to controlling shareholders reached KRW 3.47 billion, well above the KRW 866 million operating loss.

  3. 3

    More than 90% of revenue comes from overseas exports. In the second quarter of 2026, Nexpowder accounted for 83% of sales, and export shares were 53% for the US, 41% for Europe and 5% for Japan.

  4. 4

    At the end of 2025, total equity was KRW 48.1 billion, total liabilities were KRW 11.2 billion, and the debt ratio was 23.2%.

  5. 5

    Because the company posted net losses over the last four quarters, an earnings-based multiple (PER) is not calculated, and valuation is read mainly through the price-to-book ratio and the premium over net assets.

02

Business structure

NEXT BIOMEDICAL develops and sells therapeutic medical devices and was listed on KOSDAQ in August 2024. Its flagship product is the endoscopic hemostatic agent Nexpowder, and press reports said Nexpowder sales reached about KRW 13.7 billion in 2025, up 66% from the prior year.

Nexsphere-F is an embolization device aimed at musculoskeletal pain, and its second-quarter 2026 revenue was about KRW 520 million, up 144% year on year. In the second quarter of 2026, Nexpowder accounted for 83% of total revenue, and about 97% of its sales came from exports.

By region, the split was 53% US, 41% Europe and 5% Japan, and the company said Japanese sales have grown quickly since the September 2025 official launch there.

In Europe, Nexsphere-F is sold through individual distributors, and in June 2026 the company signed a distribution agreement with Terumo covering some European countries.

Unlike conventional clip or thermal coagulation methods, Nexpowder sprays powder onto a bleeding site to form a gel, and it received US FDA approval for bleeding prevention in the lower gastrointestinal tract in November 2024.

Press reports said Nexpowder is the only product cleared in the US for bleeding prevention, and Medtronic is leading post-market clinical work and marketing as a partner. Revenue is concentrated in Nexpowder and overseas exports, so product and regional concentration is pronounced. The company is classified in biopharmaceuticals, but its sales are based on medical device sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.9B₩400M7.5%
2025Q4₩3.8B-₩400M−11.6%
2026Q1₩4.1B-₩1.2B−28.9%
2026Q2₩4.9B-₩1B−20.9%
2026Q3₩5.2B-₩900M−16.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩4.9B-₩5.2B-₩7.5B−107.1%—−602.3%
2024₩9.5B-₩3.6B₩2.9B−37.5%6.3%30.2%
2025₩16.5B-₩700M-₩300M−4.4%−0.6%23.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On an annual basis, revenue rose from KRW 4.88 billion in 2023 to KRW 9.54 billion in 2024 (up 95.5%) and KRW 16.5 billion in 2025 (up 72.7%), marking two consecutive years of growth, with 2025 the largest year in the 2023 to 2025 period.

The operating loss narrowed from KRW 5.23 billion in 2023 to KRW 3.57 billion in 2024 and KRW 720 million in 2025, and the company has recorded losses for three consecutive years. The operating margin improved from -107.1% to -37.5% and then to -4.4%.

The main driver cited for revenue growth was higher Nexpowder exports. SG&A rose about 31% year on year on R&D and clinical spending, which the company described as investment in new products and global regulatory approvals.

The net loss attributable to controlling shareholders of KRW 7.52 billion in 2023 turned into a net income of KRW 2.86 billion in 2024, then returned to a net loss of KRW 311 million in 2025. Net income including non-controlling interests moved in the same direction.

Operating cash flow went from -KRW 4.16 billion in 2023 and -KRW 1.2 billion in 2024 to KRW 1.25 billion in 2025, a positive swing.

On a quarterly basis, the company posted its first quarterly operating profit of KRW 370 million in the third quarter of 2025, then an operating loss of KRW 442 million in the fourth quarter.

Operating losses were KRW 1.19 billion, KRW 1.03 billion and KRW 866 million in the first through third quarters of 2026, so the loss has narrowed since the second quarter.

Revenue bottomed at KRW 3.8 billion in the fourth quarter of 2025 (down 23.0% from the prior quarter) and then rose to KRW 4.12 billion, KRW 4.94 billion and KRW 5.25 billion across the first three quarters of 2026.

The net loss attributable to controlling shareholders reached KRW 3.47 billion in the third quarter of 2026, far larger than the operating loss, so the effect of non-operating items should be checked in the periodic report.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 4.29 billion.

05

Industry analysis

Press reports describe the global arthritis embolization treatment market as roughly KRW 5 trillion, and Nexsphere-F targets pain treatment demand within that market.

In endoscopic hemostasis, conventional clip and thermal coagulation methods are described as requiring skilled technique and having difficulty reaching some sites. Nexpowder is positioned on rapid hemostasis over wide areas and on degrading in the body, which removes the need for a second removal procedure.

In an April 2025 press report, the company's CEO said Japan accounts for about 10% of the total market and the US for about 40%. In the US bleeding-prevention segment, Nexpowder is the only cleared product, which is cited as a first-mover advantage.

The FDA clinical trial for Nexsphere-F is progressing with a target of completing patient enrollment within 2026. Results from a large domestic trial demonstrating bleeding-prevention effects were published in a gastroenterology journal, and press reports mention the possibility of listing as a standard treatment.

In terms of industry cycle, the company is in a stage where sales expansion and accumulation of clinical evidence proceed together, and unlike large biopharma companies, its operating profit is still in the loss zone.

06

Outlook

In an April 2025 press report, the company cited a break-even revenue level of KRW 15 billion. Revenue reached KRW 16.5 billion in 2025, above that level, but the operating loss still remained at KRW 720 million.

In the same report the company aimed for an annual operating profit in 2025, but the annual operating loss persisted. According to an August 2026 press report, the FDA clinical trial for Nexsphere-F targets completing patient enrollment within 2026, and clinical and regulatory work continues in the second half.

A key next checkpoint is how sales under the European distribution agreement with Terumo are reflected in second-half results. As of April 2026, the FnGuide consensus put 2026 revenue at KRW 23 billion and the operating loss at KRW 5.4 billion.

The same consensus showed 2027 revenue of KRW 35 billion and an operating profit of KRW 5.2 billion, implying a move to profitability.

Quarterly revenue of KRW 4.12 billion, KRW 4.94 billion and KRW 5.25 billion in the first three quarters of 2026 means reaching the annual estimate would require a large increase in the fourth quarter.

At its second-quarter 2026 results announcement, the company said it would keep pushing overseas sales expansion and product development in the second half. The 2026 annual report will confirm full-year operating results and fourth-quarter figures, and those will serve as the baseline for this outlook.

07

Valuation

PER
—
PBR
4.7×
ROE
-9.3%
EPS
-₩521
BPS
₩5,583
Dividend per share
₩0

An earnings-based multiple (PER) is not calculated because the company posted net losses attributable to controlling shareholders over the last four quarters. The price-to-book ratio shows a large premium of market capitalization over total equity, which stood at KRW 48.1 billion at the end of 2025.

Because the valuation leans on asset-based measures, comparisons on earnings cannot currently be made. Dividend income is effectively absent, so dividend-based comparisons are also limited.

In 2024 the company swung to net income attributable to controlling shareholders, but it returned to a net loss in 2025, and operating losses narrowed from the second quarter of 2026. However, the wider net loss in the third quarter of 2026 means earnings recovery is still limited to a narrowing operating loss.

How the valuation reads will depend on how quarterly profit and loss structure is presented in the next periodic report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Overseas sales base and product expansion

Second-quarter 2026 revenue of KRW 4.94 billion was described by the company as its highest quarterly revenue. Nexpowder sales rose about 19% from the prior quarter to roughly KRW 4.1 billion, and Nexsphere-F revenue grew 144% year on year. The June 2026 distribution deal with Terumo for some European countries widens the sales network.

Narrower losses and improved cash flow

The operating loss narrowed from KRW 5.23 billion in 2023 to KRW 3.57 billion in 2024 and KRW 720 million in 2025, and the operating margin improved from -107.1% to -4.4%. Operating cash flow turned positive at KRW 1.25 billion in 2025. On a quarterly basis, operating losses have narrowed since the second quarter of 2026.

Low-leverage balance sheet

At the end of 2025 the debt ratio was 23.2%, with total liabilities of KRW 11.2 billion and total equity of KRW 48.1 billion. Equity attributable to controlling shareholders equals total equity, so non-controlling interests have no effect. However, this strength should be weighed against the pace at which quarterly losses continue.

09

Bear factors

Quarterly losses and wider net loss

The net loss attributable to controlling shareholders reached KRW 3.47 billion in the third quarter of 2026, larger than the KRW 866 million operating loss. The company has posted losses for four consecutive quarters since the fourth quarter of 2025.

Concentration in product and region

In the second quarter of 2026 Nexpowder accounted for 83% of revenue, and about 97% of its sales were exports. The US at 53% and Europe at 41% make up most of the total, so regional concentration is high. The structure depends heavily on one product and on partner agreements.

Rising costs and missed profit targets

SG&A in the second quarter of 2026 was about KRW 4.5 billion, up roughly 15% from the prior quarter. A break-even revenue level of KRW 15 billion was cited in a 2025 press report, yet 2025 revenue of KRW 16.5 billion still left an operating loss of KRW 720 million. Clinical and R&D spending could delay the timing of an earnings recovery.

10

Risk factors

Clinical and regulatory

The FDA trial for Nexsphere-F targets completing patient enrollment within 2026, and the timing of US market entry depends on trial results and approval. The company expects new revenue to build after FDA approval. Delays or uncertain trial results could raise costs.

Partner and distribution dependence

Overseas Nexpowder sales depend on global partners such as Medtronic and on a European distributor network. The Terumo distribution right for Nexsphere-F covers only some European countries. Changes in a partner's sales strategy or contract terms would directly affect revenue.

Profitability and funding

The combined net loss over the last four quarters of KRW 4.29 billion, compared with total equity of KRW 48.1 billion at the end of 2025, is a gauge of how fast equity is declining. If R&D and clinical spending keep rising, the loss period could lengthen. Whether positive operating cash flow holds on a quarterly basis is the key question.

11

What to watch next

  1. Late December 2026

    Whether patient enrollment for the FDA clinical trial of Nexsphere-F is completed within 2026. Meeting this target would indicate the pace of the US approval timeline and clinical cost structure.

  2. Around March 2027

    Filing of the 2026 annual report, which will confirm full-year revenue, operating results and fourth-quarter figures. Results for fiscal 2025 were disclosed around March 20, 2026.

  3. Around May 2027 (expected)

    First-quarter 2027 results, on an expected schedule based on the first-quarter 2026 disclosure of May 15, 2026. This is the point to check whether the narrowing operating loss continues and the direction of the net loss attributable to controlling shareholders.

12

Overall view

NEXT BIOMEDICAL's reported results show revenue growth and a narrowing loss at the same time. Revenue for 2025 was KRW 16.5 billion, up 72.7%, the operating loss narrowed to KRW 720 million, and operating cash flow turned positive.

Most sales come from Nexpowder and overseas exports, and third-quarter 2026 revenue of KRW 5.25 billion marked three straight quarters of growth.

On the other side, losses have persisted for four consecutive quarters, and the net loss attributable to controlling shareholders widened to KRW 3.47 billion in the third quarter of 2026, well above the operating loss. Higher SG&A and clinical costs could delay an earnings recovery.

Because no earnings-based multiple is calculated, valuation is read mainly through asset-based measures. The next checkpoints are whether patient enrollment for the Nexsphere-F trial is completed by late December 2026 and the full-year operating results in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. news.nate.com
  3. hansbiz.co.kr
  4. m.news.nate.com
  5. m.news.nate.com
  6. mt.co.kr
  7. rapportian.com
  8. thebionews.net
  9. chemirang.com
  10. pharm.edaily.co.kr
  11. kr.investing.com
  12. comp.fnguide.com
  13. investing.com
  14. m.news.nate.com
  15. samsungpop.com
  16. en.edaily.co.kr
  17. dailyinvest.kr
  18. valley.town

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis